TherapeuticsMD Inc. (NASDAQ:TXMD) saw an upside of 1.72% to $0.70 after adding $0.01 on Tuesday. The 5-day average trading volume is 2,101,229 shares of the company’s common stock. It has gained $0.7379 in the past week. An average of 4,518,007 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,423,885.
TXMD’s 1-month performance is -10.30% or -$0.0643 on its low of $0.6700 reached on 09/21/21. The company’s shares have touched a 52-week low of $0.67 and high of $2.75, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, TXMD has lost -42.92% or -$0.5043. However, the current price is down -74.45%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Aug 12, 61 days have gone by since the last insider trading activity for TherapeuticsMD Inc. (TXMD). DArecca James (Chief Financial Officer) most recently sold 93,337 shares at $0.87 per share on Aug 12. This transaction cost the insider $81,203. CAO and VP Finance, Donegan Michael C, sold 4,842 shares at a price of $1.04 on May 11. Then, on May 11, General Counsel Walker Marlan D sold 21,592 shares at a price of $1.04 per share. This transaction amounted to $22,456.
TherapeuticsMD Inc. (TXMD) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 32.25 for the sector.TXMD stock has a beta of 1.83. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.54.
TherapeuticsMD Inc.’s quick ratio for the period ended June 29 was 2.00, with the current ratio over the same period at 2.10 meaning that TXMD stock is able to fulfill its debt obligations. In terms of profitability, the gross margin trailing 12 months is 79.10%. The trailing 12-month EBITDA margin is -231.33%. The firm’s gross profit as reported stood at $48.9 million against revenue of $64.87 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected TXMD to announce -$0.11 per share in earnings in its latest quarter, but it posted -$0.11, representing a 0.00% surprise. EBITDA for the quarter stood at more than -$35.41 million. TXMD stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 259.68 million, with total debt at $193.64 million. Shareholders hold equity totaling $423.82 million
Let’s look briefly at TherapeuticsMD Inc. (TXMD) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 44.57% to suggest the stock is trending Neutral, with historical volatility in this time period at 45.63%.
The stock’s 5-day moving average is $0.6982, reflecting a -4.25% or -$0.0313 change from its current price. TXMD is currently trading -2.96% above its 20-day SMA, -42.63% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -30.13% and -40.70% respectively.
Stochastic %K and %D was 14.92% and 20.71% and the average true range (ATR) pointed at 0.0347. The RSI (14) points at 42.57%, while the 14-day stochastic is at 19.35% with the period’s ATR at 0.0374. The stock’s 9-day MACD Oscillator is pointing at -0.0174 and -0.0248 on the 14-day charts.
In the most recent analyst report for TherapeuticsMD Inc. (NASDAQ: TXMD), Jefferies downgraded it to an Underperform rating. They previously had a Hold rating on the stock. Analysts offering their rating for TXMD stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate TXMD as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is TXMD’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $4.00 and a high of $5.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for TherapeuticsMD Inc. (TXMD) stock is $4.75.